Does tungsten antagonize molybdenum-dependent enzymes?

Tungsten acts as a physiological antagonist to molybdenum-dependent enzyme systems due to the chemical and structural similarities between tungstate ($WO_4^{2-}$) and molybdate ($MoO_4^{2-}$).

Mechanistic pathways

• Cofactor Substitution: Tungsten utilizes overlapping cellular transport systems to competitively displace molybdenum during the biosynthesis of the pyranopterin-based molybdenum cofactor (Moco). This leads to the formation of tungsten-substituted cofactors.
• Catalytic Inactivation: While tungsten-substituted enzymes—such as sulfite oxidase, xanthine oxidase/dehydrogenase, aldehyde oxidase, and nitrate reductase—remain structurally intact, they are catalytically impaired. Tungsten possesses a lower reduction potential and greater kinetic inertness than molybdenum, which prevents the rapid reduction-oxidation cycles required for normal electron transfer.
• Competitive Reversibility: This inhibition is reversible. Increasing molybdenum availability or supplementation competitively inhibits tungstate transport and outcompetes tungsten during de novo Moco synthesis, successfully restoring enzyme function.

Clinical and physiological implications

• Sulfite Accumulation: The inhibition of the critical molybdoenzyme sulfite oxidase impairs the body's ability to detoxify sulfites, leading directly to systemic sulfite accumulation.

Bottom line

• Tungsten directly antagonizes molybdenum-dependent enzymes by substituting for molybdenum during cofactor assembly, resulting in catalytically inactive enzymes and toxic sulfite accumulation due to restricted redox cycling; this antagonism is fully reversible by restoring molybdenum levels.